PMID- 28241064
OWN - NLM
STAT- MEDLINE
DCOM- 20170906
LR  - 20220316
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 2
DP  - 2017
TI  - Meta-analyses of comparative efficacy of antidepressant medications on peripheral 
      BDNF concentration in patients with depression.
PG  - e0172270
LID - 10.1371/journal.pone.0172270 [doi]
LID - e0172270
AB  - BACKGROUND: Brain derived neurotrophic factor (BDNF) is one of the most important 
      regulatory proteins in the pathophysiology of major depressive disorder (MDD). 
      Increasing numbers of studies have reported the relationship between serum/plasma 
      BDNF and antidepressants (ADs). However, the potential effects of several classes 
      of antidepressants on BDNF concentrations are not well known. Hence, our 
      meta-analyses aims to review the effects of differential antidepressant drugs on 
      peripheral BDNF levels in MDD and make some recommendations for future research. 
      METHODS: Electronic databases including PubMed, EMBASE, the Cochrane Library, Web 
      of Science, and PsycINFO were searched from 1980 to June 2016. The change in BDNF 
      levels were compared between baseline and post-antidepressants treatment by use 
      of the standardized mean difference (SMD) with 95% confidence intervals (CIs). 
      All statistical tests were two-sided. RESULTS: We identified 20 eligible trials 
      of antidepressants treatments for BDNF in MDD. The overall effect size for all 
      drug classes showed that BDNF levels were elevated following a course of 
      antidepressants use. For between-study heterogeneity by stratification analyses, 
      we detect that length of treatment and blood samples are significant effect 
      modifiers for BDNF levels during antidepressants treatment. While both SSRIs and 
      SNRIs could increase the BDNF levels after a period of antidepressant medication 
      treatment, sertraline was superior to other three drugs (venlafaxine, paroxetine 
      or escitalopram) in the early increase of BDNF concentrations with SMD 0.53(95% 
      CI = 0.13-0.93; P = 0.009). CONCLUSIONS: There is some evidence that treatment of 
      antidepressants appears to be effective in the increase of peripheral BDNF 
      levels. More robust evidence indicates that different types of antidepressants 
      appear to induce differential effects on the BDNF levels. Since sertraline makes 
      a particular effect on BDNF concentration within a short amount of time, there is 
      potential value in exploring its relationship with BDNF and its pharmacological 
      mechanism concerning peripheral blood BDNF. Further confirmatory trials are 
      required for both observations.
FAU - Zhou, Chanjuan
AU  - Zhou C
AD  - Department of Neurology, Yongchuan Hospital, Chongqing Medical University, 
      Chongqing, China.
FAU - Zhong, Jiaju
AU  - Zhong J
AD  - Department of Neurology, Yongchuan Hospital, Chongqing Medical University, 
      Chongqing, China.
FAU - Zou, Bin
AU  - Zou B
AD  - College of Computer and Information Science, Southwest University, Chongqing, 
      China.
FAU - Fang, Liang
AU  - Fang L
AD  - Department of Neurology, Yongchuan Hospital, Chongqing Medical University, 
      Chongqing, China.
FAU - Chen, Jianjun
AU  - Chen J
AD  - Institute of Life Sciences, Chongqing Medical University, Chongqing, China.
FAU - Deng, Xiao
AU  - Deng X
AD  - Children's Hospital of Chongqing Medical University, Chongqing Medical 
      University, Chongqing, China.
FAU - Zhang, Lin
AU  - Zhang L
AD  - College of Computer and Information Science, Southwest University, Chongqing, 
      China.
FAU - Zhao, Xiang
AU  - Zhao X
AD  - College of Computer and Information Science, Southwest University, Chongqing, 
      China.
FAU - Qu, Zehui
AU  - Qu Z
AD  - College of Computer and Information Science, Southwest University, Chongqing, 
      China.
FAU - Lei, Yang
AU  - Lei Y
AD  - Department of neurology, University-town hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Lei, Ting
AU  - Lei T
AD  - Department of Physics, University of Fribourg, Fribourg, Switzerland.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20170227
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Antidepressive Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0DHU5B8D6V (Citalopram)
RN  - 41VRH5220H (Paroxetine)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - 7D7RX5A8MO (Venlafaxine Hydrochloride)
RN  - QUC7NX6WMB (Sertraline)
SB  - IM
MH  - Antidepressive Agents/*therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Citalopram/therapeutic use
MH  - Clinical Trials as Topic
MH  - Data Interpretation, Statistical
MH  - Depression/*blood/*drug therapy
MH  - Humans
MH  - Paroxetine/therapeutic use
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Sertraline/therapeutic use
MH  - Venlafaxine Hydrochloride/therapeutic use
PMC - PMC5328267
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2017/02/28 06:00
MHDA- 2017/09/07 06:00
PMCR- 2017/02/27
CRDT- 2017/02/28 06:00
PHST- 2016/10/09 00:00 [received]
PHST- 2017/02/02 00:00 [accepted]
PHST- 2017/02/28 06:00 [entrez]
PHST- 2017/02/28 06:00 [pubmed]
PHST- 2017/09/07 06:00 [medline]
PHST- 2017/02/27 00:00 [pmc-release]
AID - PONE-D-16-40295 [pii]
AID - 10.1371/journal.pone.0172270 [doi]
PST - epublish
SO  - PLoS One. 2017 Feb 27;12(2):e0172270. doi: 10.1371/journal.pone.0172270. 
      eCollection 2017.